Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-15T05:03:40.142Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjuvants and Immune Enhancement

Published online by Cambridge University Press:  14 October 2009

Anthony C. Allison
Anthony C. Allison
Affiliation:
Dawa Corporation
Get access Rights & Permissions [Opens in a new window]

Abstract

Adjuvants increase cell-mediated and humoral immune responses to specific antigens. Used with recombinant viral antigens, they can elicit the production of T lymphocytes that lyse target cells, expressing the antigen in a genetically restricted fashion. Adjuvants can augment the production of interferon-gamma, thereby favoring the production of protective antibody isotopes, such as immuno-globulin G2a in the mouse. Modern adjuvants display the efficacy of Freund's complete adjuvant without its side effects. One such adjuvant is Syntex adjuvant formulation, a synthetic analogue of muramyl dipeptide in a microfluidized squalane/squalene-in-water emulsion. Monophosphoryl lipid A in a similar lipid emulsion is also effective. Immune-stimulating complexes of saponin and antigens elicit potent cell-mediated and humoral responses. A purified saponin component has adjuvant activity with reduced side effects; liposomes also can have adjuvant activity. Administering antigens in adjuvants can overcome low responsiveness in very young and old experimental animals and in those that are genetically low responders. Adjuvants are likely components of a new generation of recombinant and subunit vaccines.

Type
Special Section: Vaccines and Public Health: Assessing Technologies and Public Policies
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 1 , Winter 1994 , pp. 107 - 120
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Allison, A. C., & Davies, A. J. S.Requirement of thymus-dependent lymphocytes for potentiation by adjuvants of antibody formation. Nature, 1971, 233, 330–32.CrossRefGoogle ScholarPubMed
2.Allison, A. C., & Gregoriadis, G.Liposomes as immunological adjuvants. Nature, 1974, 252–53.CrossRefGoogle ScholarPubMed
3.Arden, N. H., Patricarca, P. A., & Kendal, A. P. Experiences in the use and efficacy of influenza vaccine in nursing homes. In Kendal, A. P. & Patricarca, P. A. (eds.), Options for control of influenza. New York: Alan R. Liss, 1986, 155–68.Google Scholar
4.Balfour, B. M., Drexhage, H. A., Kamperdijk, E. W., et al. Antigen-presenting cells, including Langerhans cells, veiled cells and interdigitating cells. Ciba Foundation Symposia, 1980, 84, 281–301.Google Scholar
5.Berman, P.W., Gregory, T. J., Crase, P., et al. Protection from genital herpes simplex type 2 infection by vaccination with cloned glycoprotein D. Science, 1985, 227, 1490–92.Google Scholar
6.Bomford, R.Relative adjuvant activity of Al(OH)3 and saponin is related to the immunoge-nicity of the antigen. International Archives of Allergy and Applied Immunology, 1984, 75, 280–81.Google Scholar
7.Bomford, R. Aluminum salts: Perspectives in their use as adjuvants. In Gregoriadis, G., Allison, A. C., & Poste, G. (eds.), Immunological adjuvants and vaccines. New York: Plenum Press, 1989, 35–42.CrossRefGoogle Scholar
8.Bomford, R. Saponins as immunoadjuvants. In Gregoriadis, G., Allison, A. C., & Poste, G. (eds.), Immunological adjuvants and vaccines. New York: Plenum Press, 1989, 43–46.Google Scholar
9.Byars, N. E., & Allison, A. C.Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine, 1987, 5, 223–28.Google Scholar
10.Byars, N. E., Allison, A. C., Harmon, M. W., et al. Enhancement of antibody responses to influenza B virus hemagglutinin by use of a new adjuvant formulation. Vaccine, 1990, 8, 49–56.Google Scholar
11.Byars, N. E., Fraser-Smith, E. B., Pecyk, R. A., et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine, in press.Google Scholar
12.Byars, N. E., Nakano, G. M., Welch, M., et al. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine, 1919, 9, 309–18.Google Scholar
13.Campbell, M. J., Esserman, L., Byars, N. E., et al. Development of a new therapeutic approach to B cell malignancy: The induction of immunity by the host against cell surface receptor on the tumor. International Review of Immunology, 1989, 4, 251–70.Google Scholar
14.Carayanniotis, G., & Barber, B. H.Adjuvant independent immunization by immunotar-geting antigens to MHC and non-MHC determinants in vivo. Molecular Immunology, 1991, 25, 261–67.CrossRefGoogle Scholar
15.Chedid, L., Parant, M. A., Audibert, F. M., et al. Biological activity of a new synthetic muramyl dipeptide adjuvant devoid of pyrogenicity. Infection and Immunity, 1982, 35, 417–25.CrossRefGoogle ScholarPubMed
16.Dalsgaard, K.A study of the isolation and characterization of the saponin Quil A: Evaluation of its adjuvant activity, with special reference to the application in the vaccination of cattle against foot-and-mouth disease. A eta Veterinaria Scandinavia Supplement, 1978, 69, 1–12.Google Scholar
17.Davies, P., & Allison, A. C. Secretion of macrophage enzymes in relation to the pathogen-esis of chronic inflammation. In Nelson, D. S. (ed.), Immunobiology of the macrophage. New York: Academic Press, 1976, 427–50.CrossRefGoogle Scholar
18.Ellouz, F., Adam, A., Ciorbaru, R., et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycans. Biochemical and Biophysical Research Communications, 1974, 59, 1317.CrossRefGoogle Scholar
19.Finkelman, F. D., Holmes, J., Katona, I. M., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annual Review of Immunology, 1990, 8, 303–34.Google Scholar
20.Fraser-Smith, E. G., Waters, R. V., & Matthews, T. R.Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloen-dothelial system for various muramyl dipeptide analogues, using normal and immunosup-pressed mice. Infection and Immunology, 1982, 35, 105–10.Google Scholar
21.Freund, J.The mode of action of immunologic adjuvants. Advances in Tuberculosis Research, 1956, 7, 130–48.Google Scholar
22.Geczy, A. F., Alexander, K., Bashir, H. V., et al. HLA-B27, Klebsiella and ankylosing spondylitis: Biological and chemical studies. Immunology Review, 1983, 70, 23–50.CrossRefGoogle ScholarPubMed
23.Girard, M., Kieny, M.-P., Pinter, A., et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences of the United States of America, 1991, 885, 542–46.CrossRefGoogle Scholar
24.Glenny, A. T., Pope, G. C., Waddington, H., et al., Antigenic value of toxoid precipitated by potassium alum. Journal of Pathology and Bacteriology, 1926, 29, 38–45.Google Scholar
25.Gregoriadis, G.Immunological adjuvants: A role for liposomes. Immunology Today, 1990, 11, 89–93.Google Scholar
26.Gustafson, G. L., & Rhodes, M. J.Bacterial cell wall products as adjuvants: Early inter-feron-gamma as a marker for adjuvants that enhance protective immunity. Research in Immunology, 1992, 143, 483–88.Google Scholar
27.Hunter, R. L., Strickland, F., & Kezdy, F.The adjuvant activity of nonionic block polymer surfactants: I. The role of hydrophile-lipophile balance. Journal of Immunology, 1981, 127, 1244–50.CrossRefGoogle ScholarPubMed
28.Imoto, M., Yoshimura, H., Sakaguchi, N., et al. Total synthesis of Escherichia coli lipid A. Tetrahedron Letters 1985, 26, 1545–48.Google Scholar
29.Jones, W. R., Bradley, J., Judd, S. J., et al. Phase I clinical trials of a World Health Organization birth control vaccine. Lancet, 1988, i, 1295–98.Google Scholar
30.Kaminski, M. S., Kitamura, K., Maloney, D. G., et al. Importance of antibody isotype in monoclonal anti-idiotyhpe therapy of murine B cell lymphoma: A study of hybridoma class-switch variants. Journal of Immunology, 1986, 136, 1123–30.CrossRefGoogle ScholarPubMed
31.Kenney, J. S., Hughes, B. M., & Allison, A. C. Determination of antibody affinity and concentration by solution-phase microradioimmunoassay. In Zola, H. (ed.), Laboratory methods in immunology. Boca Raton, FL: CRC Press, 1990, 209–16.Google Scholar
32.Kenney, J. S., Hughes, B. W., Masada, M. P., etal. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. Journal of Immunological Methods, 1989, 121, 157–66.Google Scholar
33.Klaus, G. G., Humphrey, J. H., Kunkl, A., et al. The follicular dendritic cell: Its role in antigen presentation and in the generation of immunological memory. Immunology Review, 1980, 53, 3–28.CrossRefGoogle ScholarPubMed
34.Letvin, N. L., Daniel, M. D., King, N. V., et al. AIDS-like disease in macaque monkeys induced by simian immunodeficiency virus: A vaccine trial. In Chanock, R. M., Lerner, R. A., Brown, F., et al. (eds.), Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1987, 209–13.Google Scholar
35.Lövgren, K., & Morein, B.The requirement for lipids for the formation of immunostimu-lating complexes (ISCOMs). Biotechnology and Applied Biochemistry, 1988, 10, 161–72.CrossRefGoogle ScholarPubMed
36.Macatonia, S. E., & Knight, S. C.Dendritic cells and T cells transfer sensitization for delayed-type hypersensitivity after skin painting with contact sensitizer. Immunology, 1989, 66, 96–99.Google Scholar
37.Marx, P. A., Pedersen, N. C., Lerche, N. W., et al. Prevention of simian acquired immunodeficiency syndrome with a formalin-inactivated Type D retrovirus vaccine. Journal of Virology, 1986, 60, 431–35.Google Scholar
38.McKercher, P. D. Oil adjuvants: Their use in veterinary biologies. In Nervig, R. M., Gough, P. M., Kaeberle, M. L., et al. (eds), Advances in carriers and adjuvants for veterinary biologies. Ames: Iowa State University Press, 1986, 115–28.Google Scholar
39.Metlay, J. P., Pure, E., & Steinman, R. M.Control of the immune response at the level of antigen-presenting cells: A comparison of the function of dendritic cells and B lymphocytes. Advances in Immunology, 1990, 47, 45–116.Google Scholar
40.Milich, D. R., & Chisari, F. V.Genetic restriction of the immune response to hepatitis B surface antigen (HBsAg): 1. Restriction of the murine humoral response to the a and d determinants of HBsAg. Journal of Immunology, 1982, 129, 320–25.Google Scholar
41.Morein, B., Lövgren, K., & Höglund, S. Immunostimulating complex (ISCOM). In Gregoriadis, G., Allison, A. C., Poste, G. (eds.), Immunological adjuvants and vaccines. New York: Plenum Press, 1989, 153–62.CrossRefGoogle Scholar
42.Morein, B., Sundquist, B., Höglund, S., et al. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 1984, 308, 457–60.CrossRefGoogle ScholarPubMed
43.Morgan, A. J., Allison, A. C., Finerty, S., et al. Validation of a first generation Epstein-Barr virus vaccine preparation suitable for human use. Journal of Medical Virology, 1989, 29, 74–78.Google Scholar
44.Morris, A. G., Lin, Y.-L., & Askonas, B. A.Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target. Nature, 1982, 295, 150–52.CrossRefGoogle Scholar
45.Murphey-Cobb, M., Martin, L. N., Davison-Fairburn, B., et al. A formalin inactivated whole simian immunodeficiency virus vaccine confers protection in macaques. Science, 1989, 246, 1293–97.Google Scholar
46.Murray, J. L., Kleineman, E. S., Cunningham, J. E., et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. Journal of Clinical Oncology, 1989, 7, 1915–25.Google Scholar
47.Nagao, S., & Tanaka, A.Muramyl dipeptide-induced adjuvant arthritis. Infectious Immunology, 1980, 28, 624–26.CrossRefGoogle ScholarPubMed
48.Nagao, S., & Tanaka, A.Necrotic inflammatory reaction induced by muramyl dipeptide in guinea pigs sensitized by tubercle bacilli. Journal of Experimental Medicine, 1985, 162, 401–12.Google Scholar
49.Newman, M. J., Wu, J.-Y., Gardner, B. H., et al. Saponin adjuvant induction of oval-bumin-specific CD8+ cytotoxic T lymphocyte responses. Journal of Immunology, 1992, 148, 2357–62.Google Scholar
50.Nicholson, K. G., Tyrrell, D. A. J., Harrison, P., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (HiNi) vaccine: Serological and clinical reactions. Journal of Biological Standards, 1979, 7, 123–31.Google Scholar
51.Playfair, J. H. L., & DeSouza, J. B.Vaccination of mice against malaria with soluble antigens: I. The effect of injection route and adjuvant. Parasite Immunology, 1986, 8, 409–14.Google Scholar
52.Ramshaw, I., Ruby, J., Ramsay, A., et al. Expression of cytokines by recombinant vaccinia viruses: A model for studying cytokines in virus infection in vivo. Immunology Review, 1992, 127, 157–82.Google Scholar
53.Reichman, L., Clark, M., Waldmann, H., et al. Reshaping human antibodies for therapy. Nature, 1988, 332, 323–27.Google Scholar
54.Reitschel, E. T., Brade, L., Schade, V., et al. Bacterial endotoxins: Relationship between chemical structure and biological activity. In Gregoriadis, G., Allison, A. C., Poste, G. (eds.), Immunological adjuvants and vaccines. New York: Plenum Press, 1989, 61–74.Google Scholar
55.Ribi, E., Ulrich, J. T., & Masihi, K. N. Immunopotentiating activities of monophosphoryl lipid A. In Majde, J. A. (ed.), Immunopharmacology of infectious diseases: Vaccine adjuvants and modulation of non-specific resistance. New York: Alan R. Liss, 1987, 101–12.Google Scholar
56.Ron, Y., & Sprent, J.T cell primary in vivo: A major role for B cells in presenting antigen to T-cells in lymph nodes. Journal of Immunology, 1987, 138, 2848–56.CrossRefGoogle Scholar
57.Spitznagel, J. K., & Allison, A. C.Mode of action of adjuvants: Effects of antibody responses to macrophage-associated bovine serum albumin. Journal of Immunology, 1970, 104, 128–39.Google Scholar
58.Szakal, A. K., Kosco, M. H., & Tew, J. G.Microanatomy of lymphoid tissue during humoral immune responses: Structure function relationships. Annual Review of Immunology, 1989, 7, 91–109.CrossRefGoogle ScholarPubMed
59.Takahashi, H., Takeshita, T., Morein, B., et al. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature, 1990, 344, 873–75.Google Scholar
60.Unanue, E. R., Askonas, B. A., & Allison, A. C.A role of macrophages in the stimulation of immune responses by adjuvants. Journal of Immunology, 1969, 103, 71–78.CrossRefGoogle ScholarPubMed
61.Unkeless, J. C., Scigliano, E., & Freedman, V. H.Structure and function of human and murine receptors for IgG. Annual Review of Immunology, 1988, 6, 251–81.Google Scholar
62.Vijay, H. M., Lavregne, G., Huang, H., et al. Preferential synthesis of IgE reaginic antibodies in rats immunized with alum adsorbed antigens. International Archives of Allergy and Applied Immunology, 1979, 59, 227–32.Google Scholar
63.Walker, B. D., Flexner, C., Paradis, T. J., et al. HIV-1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals. Science, 1988, 240, 64–66.CrossRefGoogle ScholarPubMed
64.Waters, R. V., Terrell, T. G., & Jones, G. H.Uveitis induction in the rabbit by muramyl dipeptides. Infection and Immunity, 51, 816–25.CrossRefGoogle Scholar
65.Wechsler, D. S., & Konghshavn, P. A. L.Heat-labile antibodies effect cure of Trypano-soma musculi infection in C57BL/6 mice. Journal of Immunology, 1986, 137, 2968–72.Google Scholar
66.White, R. G.The adjuvant effect of microbial products on the immune response. Annual Review of Microbiology, 1976, 30, 579–600.Google Scholar